In contrast to this, pioglitazone was found not to alter ATP production in skeletal muscle of patients, despite increasing insulin sensitivity [95], while a different study showed that 6 months of pioglitazone treatment improved the mitochondrial proteomic profile, which is disturbed in T2D [96]. The gene discussed is INS; the disease is type 2 diabetes mellitus.